HealthEquity, Inc. (NASDAQ:HQY) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

A number of other equities analysts also recently issued reports on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $56.00 price target on shares of HealthEquity in a research note on Tuesday, August 29th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $61.00 price target (up from $57.00) on shares of HealthEquity in a research note on Monday, June 12th. Chardan Capital increased their price target on shares of HealthEquity from $53.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, June 7th. Zacks Investment Research raised shares of HealthEquity from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research note on Wednesday, July 12th. Finally, TheStreet raised shares of HealthEquity from a “c” rating to a “b” rating in a research note on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $56.50.

Shares of HealthEquity (NASDAQ HQY) traded down 1.53% during mid-day trading on Friday, hitting $45.12. The stock had a trading volume of 1,500,491 shares. The stock’s 50-day moving average is $44.62 and its 200 day moving average is $45.93. HealthEquity has a 1-year low of $30.34 and a 1-year high of $54.95. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of 84.81 and a beta of 1.75.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Tuesday, September 5th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.13. HealthEquity had a net margin of 20.27% and a return on equity of 13.93%. The company had revenue of $56.90 million during the quarter, compared to the consensus estimate of $55.66 million. During the same period in the prior year, the firm earned $0.16 earnings per share. HealthEquity’s revenue was up 28.7% on a year-over-year basis. Equities research analysts predict that HealthEquity will post $0.71 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/16/healthequity-inc-hqy-rating-increased-to-sell-at-bidaskclub.html.

In other news, Director Frank Medici sold 537,102 shares of the stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $51.24, for a total transaction of $27,521,106.48. Following the sale, the director now owns 6,381 shares in the company, valued at $326,962.44. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Jon Soldan sold 25,000 shares of the stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $40.68, for a total transaction of $1,017,000.00. Following the sale, the vice president now owns 30,652 shares in the company, valued at approximately $1,246,923.36. The disclosure for this sale can be found here. Insiders have sold 1,976,064 shares of company stock valued at $100,665,521 in the last ninety days. Insiders own 29.00% of the company’s stock.

Several large investors have recently bought and sold shares of HQY. BlackRock Inc. grew its holdings in shares of HealthEquity by 157,852.9% during the first quarter. BlackRock Inc. now owns 5,589,953 shares of the company’s stock valued at $237,293,000 after buying an additional 5,586,414 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of HealthEquity by 627.9% during the second quarter. Janus Henderson Group PLC now owns 2,113,030 shares of the company’s stock valued at $105,292,000 after buying an additional 1,822,732 shares during the last quarter. FMR LLC grew its holdings in shares of HealthEquity by 45.6% during the second quarter. FMR LLC now owns 2,235,150 shares of the company’s stock valued at $111,378,000 after buying an additional 699,728 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of HealthEquity during the second quarter valued at approximately $25,822,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of HealthEquity by 47.9% during the first quarter. Bank of New York Mellon Corp now owns 816,504 shares of the company’s stock valued at $34,661,000 after buying an additional 264,604 shares during the last quarter. Hedge funds and other institutional investors own 91.86% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.